M
Mileidys Perez Alea
Researcher at University of Palermo
Publications - 4
Citations - 1375
Mileidys Perez Alea is an academic researcher from University of Palermo. The author has contributed to research in topics: Autocrine signalling & Interleukin 4. The author has an hindex of 4, co-authored 4 publications receiving 1292 citations.
Papers
More filters
Journal ArticleDOI
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.
Matilde Todaro,Mileidys Perez Alea,Anna Barbara Di Stefano,Patrizia Cammareri,Louis Vermeulen,Flora Iovino,Claudio Tripodo,Antonio Russo,Gaspare Gulotta,Jan Paul Medema,Giorgio Stassi +10 more
TL;DR: The data suggest that colon tumor growth is dictated by stem-like cells that are treatment resistant due to the autocrine production of IL-4, which strongly enhances the antitumor efficacy of standard chemotherapeutic drugs through selective sensitization of CD133(+) cells.
Journal ArticleDOI
Autocrine Production of Interleukin-4 and Interleukin-10 Is Required for Survival and Growth of Thyroid Cancer Cells
Matilde Todaro,Monica Zerilli,Lucia Ricci-Vitiani,Miriam Bini,Mileidys Perez Alea,Ada Maria Florena,Laura Miceli,Gerolama Condorelli,Sebastiano Bonventre,Giuseppe Di Gesu,Ruggero De Maria,Giorgio Stassi +11 more
TL;DR: It is shown that freshly purified thyroid cancer cells were completely refractory to CD95-induced apoptosis despite the consistent expression of Fas-associated death domain and caspase-8, and that IL-4 and IL-10 may represent key targets for the treatment of thyroid cancer.
Journal ArticleDOI
IL-4-mediated drug resistance in colon cancer stem cells.
TL;DR: The potential use of the CD133 antigen in concert with Musashi-1 as markers to identify the colon cancer stem cell population is discussed.
Journal ArticleDOI
Crucial Role of Interleukin-4 in the Survival of Colon Cancer Stem Cells
Maria Giovanna Francipane,Mileidys Perez Alea,Ylenia Lombardo,Matilde Todaro,Jan Paul Medema,Giorgio Stassi +5 more
TL;DR: Findings suggest that inhibitors of IL-4 signaling may offer a new therapeutic tool in colon carcinoma.